联交所最新资料显示，2月2日，The Goldman Sachs Group,Inc.增持爱康医疗(01789)2万股，每股作价 5.69港元，总金额为11.38万港元。增持后最新持股数目约为5620.87万股，最新持股比例为5%。 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has approved 10 innovative medical devices for special review procedures as part of the third batch of applications for 2026 [1][2] Group 1: Approved Innovative Products - The following innovative products have been granted special review status: 1. Chronic Obstructive Pulmonary Disease Assessment Software by Bojiang Life Sciences (Shanghai) Co., Ltd. [1][2] 2. Ultrasound Therapy Device by Shenzhen Tengfu Medical Technology Co., Ltd. [1][2] 3. Transcatheter Artificial Tricuspid Valve by Edwards Lifesciences LLC [1][2] 4. Transcatheter Artificial Tricuspid Valve by Jiangsu Zhenyi Medical Technology Co., Ltd. [1][2] 5. Ultrasound Thrombolysis Catheter and Stent System by Shanghai Tengfu Medical Technology Co., Ltd. [1][2] 6. Radiation Therapy Planning Software by Guoke Ion Medical Technology Co., Ltd. [1][2] 7. Implantable Cardioverter Defibrillator by Chuangling Cardiac Rhythm Management Medical Device (Shanghai) Co., Ltd. [1][2] 8. Peripheral Balloon Expandable Stent System by Zhejiang Guichuang Medical Technology Co., Ltd. [1][2] 9. Thoracoabdominal Endoscopic Surgical System by Zhi Guan Medical Company [1][2] 10. Coronary Sinus Balloon Counterpulsation System by Shanghai Micron Melody Medical Technology Co., Ltd. [1][2]

Core Viewpoint - Thermo Fisher Scientific has issued a profit warning for 2026, citing lower-than-expected annual profits and ongoing pressure from reduced U.S. academic research funding, leading to cautious customer attitudes [1][3]. Financial and Market Context - The company reported revenues of $44.56 billion in 2025, representing a 4% year-over-year increase [5]. - The ongoing reduction in U.S. academic research funding, influenced by previous government policies, has led to more cautious purchasing behavior from research institutions, which are key customers for Thermo Fisher [2][4]. Operational Adjustments - The company plans to gradually close a manufacturing facility in Franklin, Massachusetts, resulting in the layoff of 103 employees, with operations shifting to other U.S. production sites [1][3]. - The closure process is expected to be completed by the end of 2026, with layoffs starting on December 31, 2026, and potentially continuing into 2027 [2][4]. - In early January 2026, the company announced the closure of another manufacturing facility in Asheville, North Carolina, affecting 421 jobs [2][4]. Strategic Initiatives - Despite facing industry headwinds, the company is committed to enhancing its global competitiveness and has pledged to invest an additional $2 billion over the next four years in U.S. manufacturing and R&D [5]. - A new manufacturing facility covering 375,000 square feet was opened in Mebane, North Carolina, as part of this investment strategy [5]. - The company is balancing closures and new investments to maintain competitiveness and lay the groundwork for long-term growth [5].

Group 1 - The core viewpoint of the news is that 联影医疗 (United Imaging Healthcare) has shown significant financial growth in its recent quarterly report, indicating strong performance in the medical imaging equipment sector [2]. - As of February 4, 2026, the stock price of 联影医疗 closed at 129.95 yuan, reflecting a 1.82% increase with a trading volume of 54,100 hands and a total transaction amount of 695 million yuan [1]. - In the recent funding flow data, the net inflow of main funds was 44.32 million yuan, accounting for 6.38% of the total transaction amount, while retail investors experienced a net outflow of 76.86 million yuan, representing 11.06% of the total transaction amount [1]. Group 2 - For the first three quarters of 2025, 联影医疗 reported a main revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% year-on-year [2]. - The third quarter of 2025 saw a single-quarter main revenue of 2.843 billion yuan, a 75.41% increase year-on-year, and a net profit attributable to shareholders of 122 million yuan, reflecting a 143.8% year-on-year growth [2]. - The company has a debt ratio of 30.08% and a gross profit margin of 47.02%, indicating a solid financial position [2].

Core Viewpoint - Yuyue Medical (002223) is actively involved in providing high-altitude oxygen supply equipment for the construction of the Yarlung Zangbo River downstream hydropower station project, indicating a focus on expanding its service offerings in the high-altitude medical supply sector [1] Group 1 - The company and its wholly-owned subsidiary, Tibet Yuyue Medical Investment Co., Ltd., have supplied high-altitude oxygen products including central oxygen supply systems, desktop oxygen generators, portable oxygen generators, and portable oxygen inhalers for the hydropower project [1] - The company aims to continue seeking further cooperation opportunities related to the project, providing ongoing high-altitude oxygen services and health support for the Yarlung Zangbo River hydropower station [1] - Currently, the orders obtained by the company are not expected to have a significant impact on overall performance, and there remains a degree of uncertainty regarding future order acquisition [1]

Core Viewpoint - Yuyue Medical (002223) has integrated several health devices, such as blood glucose meters, blood pressure monitors, and ventilators, with Ant Group's health management system, allowing users to track and manage their health data conveniently [1] Group 1 - The company offers multiple health devices that can connect to Ant Group's health management system upon user authorization [1] - The monitoring data from these devices can be automatically synchronized to users' personal health records, facilitating long-term health management [1] - Investors are advised to refer to the company's periodic reports for specific performance details [1]

证券之星消息，截至2026年2月4日收盘，春立医疗(688236)报收于23.03元，下跌1.24%，换手率 0.74%，成交量2.14万手，成交额4912.14万元。 2月4日的资金流向数据方面，主力资金净流入283.14万元，占总成交额5.76%，游资资金净流入216.54 万元，占总成交额4.41%，散户资金净流出499.68万元，占总成交额10.17%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-04 | 23.03 | -1.24% | 283.14万 | 5.76% | 216.54万 | 4.41% | -499.68万 | -10.17% | | 2026-02-03 | 23.32 | 0.95% | 63.18万 | 1.35% | -104.25万 | -2.23% | 41.07万 | 0.88% | | 2026-02-02 | 23.10 | - ...

智通财经APP获悉，联交所最新资料显示，2月2日，The Goldman Sachs Group, Inc.增持爱康医疗 (01789)2万股，每股作价5.69港元，总金额为11.38万港元。增持后最新持股数目约为5620.87万股，最新 持股比例为5%。 ...

Core Viewpoint - The company has focused on a core strategic direction of "rapamycin drug balloons + intravascular imaging + special balloons + vascular reduction" in its cardiovascular division over the past five years, with a key real-world study confirming the leading nature of this technology route [1] Group 1 - A significant real-world study presented at the 2025 TCT Global Interventional Cardiology Conference demonstrated that rapamycin drug balloons achieved non-inferior results compared to stents in a population with over 60% complex lesions and large vessel primary lesions [1] - The study results validate the industry trend of rapamycin drug balloons replacing traditional stents [1] - The company has made systematic arrangements for years, locking in on the rapamycin drug balloon direction while simultaneously developing supporting intravascular imaging and special balloons, creating a comprehensive advantage of "technology route + product matrix + ecological synergy" [1] Group 2 - In product development, the company has a richer new product layout in the coronary artery field compared to its peers, including future vascular reduction products that will be paired with drug balloons [1] - The medical device industry has transitioned from "imitation and following" to "original competition," necessitating deep clinical cooperation with hospitals for future research and development [1] - The company has established clinical cooperation projects with several top-ranked hospitals in the domestic coronary artery industry, maintaining a leading position in original research and development [1]

Core Viewpoint - The company has a clear ability to anticipate fluctuations in raw material prices and has proactively completed raw material reserves for the first quarter of 2026 to lock in production costs [1] Group 1: Raw Material Strategy - The company will continue to adhere to a procurement strategy that emphasizes market trends over price, engaging in wave-based operations [1] - During periods of low prices for bulk trading raw materials for health protective gloves, the company will decisively purchase in excess to prepare for future price increases [1] - When anticipating a continuous decline in bulk trading raw material prices, the company will adopt a just-in-time purchasing approach to minimize costs and maintain a competitive edge [1]